NANOVELOS - Drug Release Control
Technology offered by NanoVelos demonstrates its power by transforming generics to super-generics via an innovative delivery system: they exhibit dramatically improved tumor targeting, thereby enhancing therapy efficacy while minimizing adverse effects on healthy tissues.
Nanovelos offers also an adaptation of its proprietary drug delivery system for your anticancer drug. We can conjugate highly potent drugs that struggle to enter preclinical or clinical trials due to the intolerable toxicity or fast clearance.
Company Details
- Employees
- 2
- Founded
- -
- Address
- Rakowiecka36, Warsaw,05-532,poland
- in****@****los.com
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- nanovelos.com
- HQ
- Warsaw
Nanovelos Questions
Nanovelos's website is nanovelos.com
Nanovelos's LinkedIn profile is https://pl.linkedin.com/company/nanovelos
Nanovelos has
2 employees.
View email and phone details for 2
employees at Nanovelos.
Nanovelos's industry is
Pharmaceutical Manufacturing
Nanovelos's top competitors are
Pure Biologics,
Poltreg S.a.,
Nanogroup S.a.,
Nanosanguis, Inc.,
Bowil Biotech Sp. Z O.o.,
Nanothea, Inc.,
Captor Therapeutics Sa,
Bioceltix,
Molecure,
Ryvu Therapeutics.
Nanovelos's support email address is info@nanovelos.com
Nanovelos's categories are Pharmaceutical Manufacturing
Nanovelos's founding year is 2013
